Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab histological clearance in psoriasis
NCT01537432Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing Placebo / Secukinumab with Secukinumab (2 arms). Primary endpoint: Percentage of Participants Achieving Skin Histology Response After Secukinumab Treatment From Baseline to Week 12. Started Jan 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01537432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01537432.